Browsing: HCP Access Only

Summary: The recent MULTISTARS AMI trial reveals significant findings, indicating that immediate multivessel PCI is non-inferior to staged procedures for patients with STEMI and multivessel coronary artery disease. This approach potentially alters the course of treatment by reducing serious cardiac events, thereby influencing guidelines on the optimal timing for such interventions.

On October 12th, 2023, Fapon, a leading life-science organization, signed a strategic cooperation agreement with Halodoc, the largest telehealth platform in Indonesia. This partnership brings together Fapon’s expertise in in-vitro diagnostics (IVD) technologies and integrated solutions with Halodoc’s strong sales channels and local service provisions. The partnership aims to enhance the healthcare standards in Indonesia, benefit local communities, and propel the country’s IVD industry.

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) have increased significantly in recent years due to its marked efficacy in body weight reduction in clinical trials and most recently, due to claims by celebrities and social media personalities that they have lost weight after using Ozempic (Semaglutide). While there were earlier concerns on supply shortage due to high demand of on-label and off-label use, there has been reports of a new adverse event signal that has drawn scrutiny from health authorities in the United States (US), European union (EU) and in Asia about its possible link to suicidal episodes. 

Agilent Technologies Inc. (NYSE: A) today announced the signing of a Memorandum of Understanding (MOU) with the Sarawak Infectious Disease Centre (SIDC) in East Malaysia.

Iron deficiency is present in 50% of the patients with heart failure and it is associated with worse symptoms and outcomes [1]. There have been a few studies analysing the benefit of intravenous (IV) ferric carboxymaltose in heart failure with iron deficiency. In the AFFIRM-AHF [2] trial, administration of IV ferric carboxymaltose reduced the risk of cardiovascular death and total hospitalisations for heart failure in patients hospitalized for acute heart failure.